Promonitor
Ref. GRF-PROMONITORThe Promonitor family of tests measures both drug levels and anti-drug antibody levels with validated ELISA assays to complement biological therapies for drug monitoring.
Products in this Range
14Select an item to see its reference, description and details.
Nothing found.
About the Product
The Promonitor family of tests measures both drug levels and anti-drug antibody levels with validated ELISA assays to complement biological therapies for drug monitoring.
Testing for drug bioavailability and immunogenicity includes IFX, Anti-IFX, ADL, Anti-ADL, RTX, Anti-RTX, ETN, Anti-ETN, GLM, Anti-GLM, VDZ, Anti-VDZ, UTK, and Anti-UTK. Personalize high-quality treatment of chronic inflammatory diseases with ease.
Promonitor-IFX: Internal evaluation studies have demonstrated that Promonitor IFX is able to quantify levels for the following biosimilars: CT-P13, SB2, GP1111
Promonitor-ANTI IFX: Internal evaluation studies have demonstrated that Promonitor anti-IFX is able to quantify anti-drug antibodies levels for following biosimilars: CT-P13, SB2
Promonitor-ADL: Internal evaluation studies have demonstrated that Promonitor ADL and Promonitor Anti-ADL are able to quantify the drug levels anti-drug antibodies levels for the following biosimilars: ABP501, SB5, GP 2017
Promonitor-RTX: Internal evaluation studies have demonstrated that the Promonitor RTX kit is able to quantify drug levels for the following biosimilars: CT-P10 (Truxima/Blitzima/Ritemvia/Rituzema)
Promonitor-ETN: Internal evaluation studies have demonstrated that the Promonitor ETN kit is able to quantify drug levels for the following biosimilars : SB4 (Benepali), GP2015 (Erelzi)
References: Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75(9):1693-1696. Fiorino G, Ruiz-Argüello MB, Maguregui A, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(3):601-606. Ruiz-Argüello MB, Maguregui A, Martinez A, Nagore D. P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar. J Crohns Colitis. 2019;13(S1):S265-S266.
Technical Characteristics
| Microplate size | 96 wells |
|---|---|
| Kit storage conditions | Refrigerated at 2-8°C |
| Sample | Serum |
| Serum storage conditions |
|
| Method |
|
| Standard (Promonitor-IFX) | WHO 1° international standard for IFX (NIBSC: 16/170) |
| Standard (Promonitor-ADL) | WHO 1° international standard for ADL (NIBSC code: 17/236) |
Key Features
- Optimized Therapy: Refine treatment of chronic inflammatory diseases with a individualized treatment for every patient enabling a personalized approach to therapy with biologics. Promonitor provides an early warning if the treatment regime may require modification.
- Cost Effective: Reduce the use of ineffective treatment strategies, allowing a more efficient use of available resources. Effectively manage resources with the information provided by Promonitor.
- Easy to use: Quickly generate easy to interpret results with ELISA-based tests and readily available equipment in 4 simple steps and 30 mins of hand-on time with precoated microplates and ready-to-use reagents.
- Flexible: Expand lab operations and workflow with multiple tests and configurations and test both drug levels and anti-drug antibody levels in manual or automated modes.
- High-quality: Results you can rely on with high specificity and sensitivity testing supported by a large number of peer-reviewed articles and referenced in over 100 publications.
- Monitoring Biosimilars: Evaluation studies have demonstrated that Promonitor kits are able to quantify not only biological drug levels, but also biosimilar drugs.
Technical Information
No technical information available for this product.
Compatibility
No compatibility information available for this product.
Packaging
No packaging information available for this product.